DrSeq IRD · Inherited Retinal Disease Panel

Genetic answers for inherited retinal disease. Built for India.

DrSeq IRD is Nucleome’s exome-based genetic test for inherited retinal diseases. It combines a proven short-read sequencing workflow with AI-based variant–phenotype correlation and trio analysis, to give Indian patients and families a clearer genetic diagnosis.

500+
genes covered
13
phenotype-specific panels + 1 comprehensive panel
500
samples in the validation cohort
AI + Trio
variant–phenotype correlation and inheritance

Three challenges stand in the way of an IRD diagnosis in India

Inherited retinal diseases (IRDs) damage the light-sensing tissue of the eye and can lead to progressive vision loss. For many families in India, an accurate genetic diagnosis remains difficult.

High disease burden
1 in 930
urban population
1 in 372
rural population
Reported figures — common enough to be a real public-health concern.
Diagnostic delays
  • Missed medical intervention — treatment often depends on knowing the causative gene
  • Exclusion from clinical trials — which usually require a confirmed molecular diagnosis
  • Elevated family-planning risks — families cannot be accurately counselled on recurrence
Representation gap
52–74%
reported diagnostic yield (Britten-Jones et al., 2023)
40–60%
of India-specific variants may be absent from global databases
Tools built only on international data can miss variants that matter for Indian patients.

A short-read exome panel with AI-based variant–phenotype correlation

DrSeq IRD is Nucleome’s whole-exome-sequencing-based panel for inherited retinal diseases. It combines a standard, proven sequencing workflow with an AI-powered step that links rare variants to disease phenotypes.

500+genes covered
13phenotype panels + 1 comprehensive panel
NovaSeq 6000whole exomes, Illumina
hg38reference genome
ClinVar, dbSNP & ExACvariant annotation
Trio analysisAR, AD and X-linked inheritance

Validated on a real-world cohort

Developed and tested on 500 blood samples. Including relatives enables trio analysis, which helps determine how a variant is inherited.

500blood samples
293patients
207relatives

AI correlation turns exome variants into phenotype-linked results

InputBlood samplesPatient ± relatives; whole exome on NovaSeq 6000
→
Step 1Primary analysisQuality control, read trimming and alignment to hg38
→
Step 2Secondary analysisVariant calling and filtering; ClinVar, dbSNP, ExAC annotation
→
Step 3 · ◆ AI/MLAI correlationAI links rare variants to IRD phenotypes
→
ResultPhenotype-linked variantsTrio data resolves AR, AD and X-linked inheritance
Intellectual property. Patent application no. 202441085453 has been filed (07 November 2025), and the freedom-to-operate assessment has been received.

13 phenotypes, led by retinitis pigmentosa at 372 genes

Non-syndromic IRDs affect the eye only. Syndromic IRDs affect other tissues and organs as well — for example, Usher syndrome causes hearing loss in addition to vision loss. Numbers show the genes associated with each phenotype.

Non-syndromic IRDs

Affect the eye only

Photoreceptor dysfunction

Retinitis pigmentosa
372
Congenital stationary night blindness (CSNB)
185
Cone dystrophy
26
Cone-rod dystrophy
95
Leber congenital amaurosis
66
Achromatopsia
26

Maculopathies

Stargardt disease
15
Bestrophinopathy
4

Syndromic IRDs

Affect other tissues and organs as well
Usher syndrome
89
Bardet-Biedl syndrome
67

Other phenotypes

Additional retinal phenotypes
Macular dystrophy
105
Vitelliform macular dystrophy 2
17
Choroideremia
17

Genes can be associated with more than one phenotype; the comprehensive panel covers more than 500 genes in total.

Exome sequencing in a South Indian retinitis pigmentosa cohort

Retinitis pigmentosa (RP) is the most common inherited retinal disease. In a prospective study published in Ophthalmology Science in 2026, Aravind Eye Hospital, Coimbatore, used whole-exome sequencing to find the genetic cause of RP in 109 unrelated patients. The exome sequencing was performed by Nucleome Informatics.

Study at a glance

SettingAravind Registry for Inherited Diseases of the Eye (ARIDE), Aravind Eye Hospital, Coimbatore
Participants109 unrelated patients (113 affected people including 4 relatives). Mean age 39.3 years (range 15 to 72); 58.7% male
EnrolmentConsecutive patients, regardless of ability to pay for testing (September 2024 to March 2025)
Clinical types83.5% non-syndromic RP, 9.2% syndromic RP, 6.4% atypical RP, 0.9% rod-cone dystrophy
SequencingWhole exome (Twist Exome 2.0) on the Illumina NovaSeq 6000, 2 × 150 bp, hg38. Mean on-target depth about 50 to 80×, more than 94% of target bases at 20× or more
InterpretationACMG/AMP classification; each case labelled solved, possibly solved, inconclusive or unsolved using rules set in advance

Headline results

45.9%molecular diagnosis (50 of 109)
38.5%solved — cause identified (42)
186rare variants in 92 genes
88%of diagnoses autosomal recessive
Solved (42)Possibly solved (8, 7.3%)Inconclusive (45)Unsolved (14)

Key results

  • 186 rare variants in 92 genes. 26 were pathogenic and 33 likely pathogenic; the other 127 (68.3%) were variants of uncertain significance.
  • Four genes explained 42% of diagnoses. EYS and USH2A (7 patients each), ADGRV1 (4) and MFSD8 (3) accounted for 21 of the 50 diagnosed patients.
  • Mostly recessive disease. 88% of diagnoses (44 of 50) were autosomal recessive, 8% autosomal dominant and 4% X-linked (RPGR).
  • Consanguinity shaped the results. All 17 diagnosed recessive cases from consanguineous families were homozygous, as were 68% from families without reported consanguinity (P = 0.013). Yield was 51.4% vs 41.7%, a difference that was not statistically significant.
  • Mostly loss-of-function variants. 76.3% of the 59 pathogenic or likely pathogenic variants were predicted to switch off the gene.

Findings worth highlighting

A regional gene spectrum

An earlier panel-based South Indian study found CERKL to be the leading gene (21%). CERKL was absent here, while ADGRV1 and MFSD8 stood out — one centre’s gene catalogue should not be assumed to hold across the region.

Recurrent and possible founder variants

MFSD8 c.1361T>C, an established South Asian founder variant, was found homozygous in 3 unrelated patients. EYS c.4321C>T and ADGRV1 c.14329C>T each recurred in 3 unrelated patients and are candidate founder alleles.

Syndromic disease can look like isolated RP

ADGRV1, linked to Usher syndrome type 2C, was the cause in 4 patients who presented with isolated RP. The authors recommend hearing tests in such cases, as the diagnosis affects counselling, monitoring and trial eligibility.

The variant-classification gap

The 68.3% share of uncertain variants reflects how poorly South Asian variants are represented in gnomAD and ClinVar. The authors propose testing relatives, depositing curated variants in ClinVar, re-analysis every 18 months and WGS for unresolved families.

Why it matters. A confirmed molecular diagnosis is increasingly a prerequisite for genetic counselling, clinical-trial eligibility and gene-directed therapies, such as those in development for USH2A, RPGR and RHO. The study shows nearly half of these patients could be given a molecular diagnosis, and that region-specific data are needed to close the rest of the gap. It also underlines three needs DrSeq IRD is designed to address: coverage well beyond a small fixed gene set, inclusion of syndromic phenotypes such as Usher syndrome, and family (trio) data to resolve inheritance.

Limitations noted by the authors: single centre, no systematic parental sequencing for phasing, and exome sequencing cannot detect deep intronic, repeat-expansion or many structural variants.
Source: Jaju S, Sivagnanam J, et al. Ophthalmology Science 2026;6:101341.

Designed for Indian patients and families

What sets the panel apart, from our team in Hyderabad.

Built for India

Developed and validated on an Indian cohort to close the representation gap left by global variant databases.

AI variant–phenotype correlation

An AI step links rare variants to IRD phenotypes, focusing attention on the variants most likely to explain the condition.

Trio analysis

Testing relatives resolves autosomal recessive, autosomal dominant and X-linked inheritance for clearer family counselling.

Flexible panel choice

Choose a phenotype-specific panel or the comprehensive IRD panel covering more than 500 genes.

Proven sequencing workflow

Whole exomes on the Illumina NovaSeq 6000, aligned to hg38 and annotated against ClinVar, dbSNP and ExAC.

Patent application filed

Patent application no. 202441085453 filed, with the freedom-to-operate assessment received.

Frequently asked, in plain language

For clinicians, patients and families considering IRD genetic testing.

basicWhat are inherited retinal diseases?
Inherited retinal diseases (IRDs) are a group of genetic conditions that damage the light-sensing tissue of the eye and can lead to progressive vision loss. Examples include retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis and Usher syndrome.
basicWhy does a genetic diagnosis matter for IRDs?
Treatment and management decisions often depend on knowing the causative gene, clinical trials usually require a confirmed molecular diagnosis, and families need it to be accurately counselled on inheritance and recurrence risk.
basicWhat is the difference between syndromic and non-syndromic IRDs?
Non-syndromic IRDs affect the eye only. Syndromic IRDs affect other tissues and organs as well. For example, Usher syndrome causes hearing loss in addition to vision loss.
intermediateCan I order a panel for one phenotype, or do I need the full panel?
Both are available. DrSeq IRD is offered as phenotype-specific panels covering 13 phenotypes, plus one comprehensive IRD panel covering more than 500 genes.
intermediateWhy do you ask for samples from relatives?
Testing relatives allows trio analysis, which helps determine how a variant is inherited: autosomal recessive (AR), autosomal dominant (AD) or X-linked.
intermediateWhat does the AI step do?
After standard variant calling and annotation, an AI step links rare variants to IRD phenotypes. Trio data then resolves the inheritance pattern. This helps prioritise the variants most likely to explain the patient’s condition.
advancedWhy does an India-specific approach matter?
An estimated 40–60% of India-specific variants may be absent from global databases, so tools built only on international reference data can miss variants that matter for Indian patients.
advancedHow was the panel validated?
DrSeq IRD was developed and tested on 500 blood samples: 293 patients and 207 relatives, sequenced as whole exomes on the Illumina NovaSeq 6000 and analysed against the hg38 reference genome.

Key literature & sources

  1. Britten-Jones AC, Gocuk SA, Goh KL, Huq A, Edwards TL, Ayton LN. The diagnostic yield of next generation sequencing in inherited retinal diseases: a systematic review and meta-analysis. Am J Ophthalmol 2023;249:57–73. doi:10.1016/j.ajo.2022.12.027
  2. Jaju S, Sivagnanam J, et al. Whole-exome sequencing in a consanguinity-enriched South Indian retinitis pigmentosa cohort: diagnostic yield and molecular spectrum. Ophthalmology Science 2026;6:101341. doi:10.1016/j.xops.2026.101341